Table 3.
Univariate analyses
| Outcomes | Reduced-intensity regimens | Myeloablative regimens | P | ||
|---|---|---|---|---|---|
| Events/Evaluable cases | Probability (95% CI), % | Events/Evaluable cases | Probability (95% CI), % | ||
| At day 28 | |||||
| Neutrophil recovery | 37/39 | 87 (75-96) | 130/139 | 84 (78-90) | .11 |
| At day 100 | |||||
| Platelet recovery | 34/38 | 89 (78-97) | 117/139 | 82 (76-88) | .11 |
| At day 100 | |||||
| Grades 2-4 acute GVHD | 12/39 | 28 (15-43) | 57/141 | 39 (31-47) | .22 |
| At 5 y | |||||
| Chronic GVHD | 17/38 | 46 (30-62) | 50/140 | 37 (29-46) | .38 |
| Transplant-related mortality | 5/39 | 16 (5-31) | 20/141 | 16 (10-22) | .73 |
| Relapse | 15/39 | 39 (24-54) | 54/141 | 39 (30-47) | .95 |
| Leukemia-free survival | 20/39 | 46 (29-63) | 74/141 | 46 (37-55) | .82 |
| Overall survival | 20/39 | 45 (29-62) | 69/141 | 48 (39-56) | .99 |